Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493467 · ClinicalTrials.gov registry record · Phase 2
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00493467: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00493467 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493467, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find out if giving (Rituxan) rituximab with 90Y (ibritumomab tiuxetan) (90 Y Zevalin®) may be effective in treating low-grade lymphoma. The safety of this combination treatment will also be studied.
Interventions
- DRUG Rituximab
- DRUG Ibritumomab Tiuxetan (Zevalin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-06 |
| Est. Completion | 2022-08-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00493467
The ClinicalTrials.gov registry entry for NCT00493467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00493467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00493467 about?
NCT00493467 is a clinical study titled "Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas". The goal of this clinical research study is to find out if giving (Rituxan) rituximab with 90Y (ibritumomab tiuxetan) (90 Y Zevalin®) may be effective in treating low-grade lymphoma. The safety of this combination treatment will also be studied.
What is the current status of trial NCT00493467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2006-06. Estimated completion is 2022-08-11.
What interventions are being tested in trial NCT00493467?
The interventions under investigation include: Rituximab (DRUG), Ibritumomab Tiuxetan (Zevalin) (DRUG).
Who is sponsoring clinical trial NCT00493467?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.